PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Price & Overview
NASDAQ:PACB • US69404D1081
Current stock price
The current stock price of PACB is 1.69 USD. Today PACB is up by 3.68%. In the past month the price increased by 20.71%. In the past year, price increased by 44.44%.
PACB Key Statistics
- Market Cap
- 510.38M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.83
- Dividend Yield
- N/A
PACB Stock Performance
PACB Stock Chart
PACB Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PACB. When comparing the yearly performance of all stocks, PACB turns out to be only a medium performer in the overall market: it outperformed 53.07% of all stocks.
PACB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PACB. PACB has a bad profitability rating. Also its financial health evaluation is rather negative.
PACB Earnings
On April 7, 2026 PACB reported an EPS of -0.12 and a revenue of 44.65M. The company beat EPS expectations (20.24% surprise) and beat revenue expectations (2.91% surprise).
PACB Forecast & Estimates
16 analysts have analysed PACB and the average price target is 2.3 USD. This implies a price increase of 35.8% is expected in the next year compared to the current price of 1.69.
For the next year, analysts expect an EPS growth of 71.72% and a revenue growth 10.52% for PACB
PACB Groups
Sector & Classification
PACB Financial Highlights
Over the last trailing twelve months PACB reported a non-GAAP Earnings per Share(EPS) of -1.83. The EPS decreased by -11.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.68% | ||
| ROE | -10214.54% | ||
| Debt/Equity | 120.65 |
PACB Ownership
PACB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.23 | 191.684B | ||
| DHR | DANAHER CORP | 22.93 | 137.138B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 147.41 | 46.589B | ||
| A | AGILENT TECHNOLOGIES INC | 18.14 | 33.417B | ||
| WAT | WATERS CORP | 22.54 | 31.298B | ||
| IQV | IQVIA HOLDINGS INC | 13.76 | 28.865B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 28.55 | 26.14B | ||
| ILMN | ILLUMINA INC | 25.7 | 20.293B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 33.75 | 19.448B | ||
| MEDP | MEDPACE HOLDINGS INC | 29.82 | 14.727B | ||
| RVTY | REVVITY INC | 17.07 | 10.01B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 9.729B | ||
| TECH | BIO-TECHNE CORP | 26.66 | 8.974B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PACB
Company Profile
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Company Info
IPO: 2010-10-27
PACIFIC BIOSCIENCES OF CALIF
1305 O'brien Drive
Menlo Park CALIFORNIA 94025 US
CEO: Christian O. Henry
Employees: 485
Phone: 16505218000
PACIFIC BIOSCIENCES OF CALIF / PACB FAQ
What does PACIFIC BIOSCIENCES OF CALIF do?
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
What is the stock price of PACIFIC BIOSCIENCES OF CALIF today?
The current stock price of PACB is 1.69 USD. The price increased by 3.68% in the last trading session.
Does PACB stock pay dividends?
PACB does not pay a dividend.
How is the ChartMill rating for PACIFIC BIOSCIENCES OF CALIF?
PACB has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for PACB stock?
16 analysts have analysed PACB and the average price target is 2.3 USD. This implies a price increase of 35.8% is expected in the next year compared to the current price of 1.69.
Would investing in PACIFIC BIOSCIENCES OF CALIF be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PACB.
What is the outstanding short interest for PACIFIC BIOSCIENCES OF CALIF?
The outstanding short interest for PACIFIC BIOSCIENCES OF CALIF (PACB) is 16.68% of its float.